



Prospectus

Chimeric Therapeutics Limited ACN 638 835 828

For the offer of:

- (a) one Attaching Option for every one Placement Share subscribed for by the Placement Subscribers under the Placement exercisable at \$0.005 each on or before 31 December 2030 (**Attaching Options Offer**);
- (b) Convertible Notes to the Noteholder with an aggregate face value of \$4,000,000 and a maturity date which is the date that is 12 months after the purchase of the Convertible Notes (**Convertible Note Offer**); and
- (c) Warrants to the Noteholder with an aggregate value of \$2,000,000 and an exercise price of \$25,000,000 divided by the number of Shares on issue immediately before the exercise of the relevant Warrant (**Warrant Offer**),
(together, the **Offers**), and for
- (d) up to 50,000,000 Adviser Options to PAC Partners Securities Pty Ltd and Taylor Collison Limited as Joint Lead Managers of the Offers (**Adviser Options**).

This is an important document that requires your immediate attention. It should be read in its entirety. This Prospectus is a transaction-specific prospectus issued in accordance with section 713 of the Corporations Act. If you have any queries about any part of the Prospectus, please contact your professional advisor without delay. The Securities offered by this Prospectus should be considered speculative.

The distribution of this Prospectus, and the offer of securities, is restricted outside Australia.

NOT FOR RELEASE TO U.S. WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES WHERE IT WOULD BE ILLEGAL TO DO SO, EXCEPT BY THE COMPANY TO US INSTITUTIONAL INVESTORS WHO PARTICIPATED IN THE OFFER

Joint Lead Managers



Legal Advisor



Table of contents

IMPORTANT NOTICES	2
1 Investment overview	4
2 Chimeric – the business	14
3 Details and effect of the Offers	17
4 How to apply	22
5 Financial information	23
6 Risk factors	25
7 Material agreements	30
8 Additional information	34
9 Glossary	41
Corporate directory	44
Annexure A	45
Attaching Option terms	45
Annexure B	47
Adviser Option terms	47
Annexure C	49
Convertible Note terms	49
Annexure D	51
Warrant terms	51

IMPORTANT NOTICES

General

This Prospectus is dated 23 March 2026. A copy of this Prospectus was lodged with ASIC on that date. Neither ASIC nor ASX takes any responsibility for the contents of this Prospectus or the merits of any investment under this Prospectus. No New Securities will be allotted or transferred on the basis of this Prospectus after the expiry date. This Prospectus expires on 23 April 2027.

No person may give any information or make a representation about the Offers, which is not in this Prospectus. Information or representations not in this Prospectus must not be relied on as authorised by the Company, or any other person, in connection with the Offers.

This Prospectus provides information for investors to decide if they wish to invest in Chimeric. Read this document in its entirety. Examine the assumptions underlying the risk factors that could affect the financial performance of Chimeric. Consider these factors carefully in light of your personal financial circumstances. Seek professional advice from your accountant, stockbroker, lawyer or other professional adviser before deciding whether to invest. The Offers do not take into account the investment objectives, financial situation or needs of particular investors.

Transaction Specific Prospectus

This Prospectus is a transaction specific prospectus for an offer of options to acquire continuously quoted securities (as defined in the Corporations Act) and has been prepared in accordance with section 713 of the Corporations Act. It does not contain the same level of disclosure as an initial public offering prospectus. In making representations in this Prospectus regard has been had to the fact that the Company is a disclosing entity for the purposes of the Corporations Act and certain matters may reasonably be expected to be known to investors and professional advisers that potential investors may consult.

Risk Factors

Potential investors should be aware that subscribing for, or exercising (as the case may be) the New Securities involves a number of risks. The key risk factors of which investors should be aware of are set out in Section 6 of this Prospectus. These risks together with other general risks applicable to all investments in listed securities not specifically referred to, may affect the value of the New Securities in the future. Accordingly, an investment in the Company should be considered highly speculative. Potential investors should consider consulting their professional advisers before deciding whether to apply for New Securities pursuant to this Prospectus.

International offer restrictions

No action has been taken to register or qualify the New Securities in any jurisdiction outside Australia, or otherwise to permit a public offering of the New Securities outside Australia.

The Prospectus does not constitute an offer or invitation in any jurisdiction where, or to any person to whom, the offer or invitation would be unlawful. The distribution of this Prospectus in jurisdictions outside Australia may be restricted by law and persons who come into possession of this Prospectus should observe any of those restrictions, including those set forth in Section 2.4. In particular, this Prospectus may not be distributed in the United States or in any jurisdiction where it would be illegal. Any failure to comply with the restrictions may constitute a violation of applicable securities laws.

In particular, this Prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The New Securities (including the underlying Shares) have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements under the US Securities Act and any applicable US state securities laws.

Forward-looking statements

Statements in this Prospectus may be forward looking statements.

Forward looking statements can be identified by the use of forward-looking terminology such as, but not limited to, 'may', 'will', 'expect', 'anticipate', 'estimate', 'would be', 'believe', or 'continue' or the negative or other variations of comparable terminology. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. The Directors' expectations, beliefs and projections are expressed in good faith and are believed to have a reasonable basis. They are based on, among other sources, the examination of historical operating trends, data in the Company's records and other data available from third parties. There can be no assurance, however, that the Directors' expectations, beliefs or projections will give the results projected in the forward-looking statements. Investors should not place undue reliance on these forward-looking statements.

Additional risk factors that could cause actual results to differ materially from those indicated in the forward-looking statements are set out in Section 6.

Publicly available information

Information about the Company is publicly available and can be obtained from ASIC and ASX (including the ASX website at www.asx.com.au). The contents of any website or ASIC or ASX filing by the Company are not incorporated into this Prospectus and do not constitute part of the Offers. This Prospectus is intended to be read in conjunction with the publicly available information in relation to the Company which has been notified to ASX. Investors should therefore have regard to the other publicly available information in relation to the Company before making a decision whether or not to invest in the Company or subscribe for the New Securities.

The Company has not authorised any person to give any information or make any representation in connection with an offer which is not contained in this Prospectus. Any such extraneous information or representation may not be relied upon as having been authorised by the Company in connection with this Prospectus.

Taxation implications

The Directors do not consider it appropriate to give Shareholders advice regarding the taxation consequences of applying for Securities under this Prospectus. The Company, its advisers and its officers do not accept any responsibility or liability for any such

taxation consequences to Shareholders. As a result, investors should consult their professional tax adviser in connection with applying for Securities under this Prospectus.

Disclaimer of representations

No person is authorised to provide any information or to make any representation in connection with the Offers that is not contained in this Prospectus. Any information or representations not contained in this Prospectus may not be relied upon as having been authorised by the Company, the Joint Lead Managers, any of their respective related bodies corporate and affiliates, nor any of their respective directors, officers, partners, employees and agents in connection with the Offers. None of the Company, the Joint Lead Managers, any of their related bodies corporate and affiliates, or any of their respective directors, officers, partners, employees, representatives or agents have authorised or caused the issue of this Prospectus or any action taken by you on the basis of such information. To the maximum extent permitted by law, the Company, the Joint Lead Managers, their related bodies corporate and affiliates and each of their directors, officers, partners, employees, representatives or agents exclude and disclaim all liability for any expenses, losses, damages or costs incurred by you as a result of your participation in the Offers and this Prospectus being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. None of the Company, the Joint Lead Managers, any of its related bodies corporate and affiliates, or any of their respective directors, officers, partners, employees, representatives or agents make any recommendations as to whether you or your related parties should participate in the Offers, nor do they make any representations or warranties to you concerning the Offers or any information, and you represent, warrant and agree that you have not relied on any statements made by the Company, the Joint Lead Managers, any of their related bodies corporate and affiliates or any of their respective directors, officers, partners, employees, representatives or agents in relation to the New Securities or the Offers generally. The Joint Lead Managers may also hold interests in the securities of the Company or earn brokerage, fees or other benefits from the Company. The engagement of the Joint Lead Managers by the Company is not intended to create any agency, fiduciary or other relationship between the Joint Lead Managers or any other investor. Determination of eligibility of investors for the purposes of the Offers is determined by reference to a number of matters, including legal requirements and regulatory requirements, logistical and registry constraints and the discretion of the Company and the Joint Lead Managers. To the maximum extent permitted by law, the Company, the Joint Lead Managers, their respective related bodies corporate and affiliates, and their respective directors, officers, partners, employees and agents expressly disclaim any duty or liability (including for negligence) in respect of that determination and the exercise or otherwise of that discretion. To the maximum extent permitted by law, the Joint Lead Managers, their related bodies corporate and affiliates, and their respective directors, officers, partners, employees and agents expressly disclaim all liability in respect of, makes no representation regarding and takes no responsibility for any part of this Prospectus.

Electronic prospectus

This Prospectus is available electronically at www.chimerictherapeutics.com. The Application Form attached to the electronic version of this Prospectus must be used within Australia. Electronic versions of this Prospectus should be downloaded and read in their entirety. Obtain a paper copy of the Prospectus (free of charge) by telephoning 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia). Applications for New Securities may only be made on the Application Form attached to this Prospectus or in its paper copy form downloaded in its entirety from www.chimerictherapeutics.com. The electronic version of the Prospectus is available only for residents of Australia.

Exposure period

No exposure period applies to this Prospectus by operation of *ASIC Corporations (Exposure Period) Instrument 2016/74*.

Privacy

The Company and the Share Registry collect, hold and use personal information received from you to communicate and provide services to you as a Shareholder. The Company may disclose your personal information to its agents, service providers (such as the share registry) and government bodies. The Company's privacy policy sets out how you may access, correct and update the personal information that the Company holds about you, how you can complain about privacy related matters and how the Company responds to complaints.

Defined terms

Capitalised terms used in this Prospectus are defined in the Glossary.

Currency

Monetary amounts shown in this Prospectus are expressed in Australian dollars unless otherwise stated.

Photographs and diagrams

Photographs used in this Prospectus without descriptions are only for illustration. The people shown are not endorsing this Prospectus or its contents. Diagrams used in this Prospectus may not be drawn to scale. The assets depicted in photographs in this Prospectus are not assets of the Company unless otherwise stated.

THIS DOCUMENT IS IMPORTANT AND SHOULD BE READ IN ITS ENTIRETY

1 Investment overview

1.1 Background

As announced on 23 December 2025 and subsequently on 25 February 2026, Chimeric is currently undertaking an equity raise to raise gross funds of up to approximately \$8.4 million to support its clinical trial pipeline and otherwise for general working capital of the Company (**Equity Raise**). The Equity Raise involves:

- (a) a two-tranche placement to sophisticated and professional investors (**Placement Subscribers**) through the issue of up to 1,466,666,665 Shares (**Placement**) as follows:
 - (i) 466,666,665 Shares on 31 December 2025 and 309,900,722 Shares on 7 January 2026, all at an issue price of \$0.003 per Share (**Tranche 1**); and
 - (ii) subject to Shareholder approval at the EGM, up to 690,099,278 Shares at an issue price of \$0.003 per Share (**Tranche 2**),(together, **Placement Shares**);
- (b) subject to Shareholder approval at the upcoming EGM Placement Subscribers will receive one Option for every Placement Share issued, exercisable at \$0.005 each on or before 31 December 2030 (**Attaching Options**);
- (c) a \$4.0 million (before costs) Convertible Note and associated Warrants committed by a US institutional investor.

The Company does not intend to seek quotation of the Attaching Options on the ASX.

The Offers are jointly managed by PAC Partners Securities Pty Ltd and Taylor Collison Limited, who will be issued Adviser Options under the Adviser Option Offer on account of professional services provided to the Company.

By receiving the Attaching Options, Convertible Notes and Warrants, each person represents and warrants that it (and any person for whom it is acting):

- if in Australia, is a non-disclosure exempt party under section 708 of the Corporations Act, including a “sophisticated investor” pursuant to 708(8), a “professional investor” pursuant to section 708(11), or the Offers have been made through a financial services licensee in accordance with the conditions under section 708(10);
- if in Hong Kong, is a “professional investor” (as defined in the Securities and Futures Ordinance of Hong Kong, Chapter 571 of the Laws of Hong Kong);
- if in New Zealand, is a person who (i) is an investment business within the meaning of clause 37 of Schedule 1 of the Financial Markets Conduct Act 2013 (New Zealand) (the “FMC Act”), (ii) meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act, (iii) is large within the meaning of clause 39 of Schedule 1 of the FMC Act, (iv) is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act or (v) is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act (and, if an eligible investor, have provided the necessary certification);
- if in Singapore, is an “institutional investor” or an “accredited investor” (as such terms are defined in the Securities and Futures Act 2001 of Singapore (“SFA”));

- will not distribute this Prospectus in the United States or to any person acting for the account or benefit of a person in the United States where it would be illegal to do so, except by the Company to US institutional investors who participated in the Offer; and
- it understands that the Attaching Options, Convertible Notes and Warrants, and the underlying ordinary shares, have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

The Prospectus

This Prospectus has been prepared for the Offers so the relief provided under *ASIC Corporations (Sale Offers That Do Not Need Disclosure) Instrument 2016/80*, with respect to the on-sale provisions of section 707 of the Corporations Act, is available. If the options, convertible notes and warrants are issued with disclosure under this Prospectus, then the Shares issued upon the exercise of any of the options, convertible notes and warrants can be on-sold within 12 months of their issue without a disclosure document being required for that on-sale, as the options, convertible notes and warrants are issued with disclosure and the exercise of the options, convertible notes and warrants does not involve any further offer.

The Attaching Options Offer is only available to Placement Subscribers.

The Adviser Options are only available to PAC Partners Securities Pty Ltd and Taylor Collison Limited as Joint Lead Managers of the Offers.

The Convertible Note Offer and Warrant Offer are only available to those who are personally invited to accept the Convertible Note and Warrant Offers, being the US institutional investor.

1.2 Summary of Offers details

Attaching Options

Terms of Offer	Number or value
Attaching Options to be issued to Placement Subscribers under the Attaching Options Offer (subject to shareholder approval, expected to be issued on or about 24 April 2026)	1,466,666,665
Total amount to be raised under the Placement (before the exercise of any Options)	\$ 4,400,000
Total amount to be raised if all available Options offered under the Attaching Options Offer are issued and exercised	\$ 7,333,333

Convertible Notes

Terms of Offer	Details
Face value per Convertible Note	\$1,000 per Convertible Note
Conversion price per Convertible Note	A 25% discount to the lowest traded price of Shares on ASX during the 10 Actual Trading Days prior to the Conversion Notice Date

Terms of Offer	Details
Total number of Convertible Notes offered under this Prospectus	4,000
Conversion rights	The Noteholder will have the right but not the obligation to convert the Convertible Notes into Shares.

Warrants

Terms of Offer	Details
Value of Warrants	\$2,000,000
Face value per Warrant	\$1,000 per Warrant
Total number of Warrants to be issued offered under this Prospectus	2,000
Exercise of Warrants	The number of Warrant Shares to be issued upon each exercise of a Warrant will be determined as follows, rounded up to the nearest whole number: A = B ÷ C A = the number of Warrant Shares to be issued; B = the total Face Value of the Warrant in the event of a full exercise, or in the event of a partial exercise, such amount determined by the Noteholder (Exercised Amount); C = the Exercise Price, calculated immediately prior to exercise of the Warrant.
Warrant Exercise Price	The Exercise Price, in relation to any Warrant being exercised (whether in part or in full) means the price per Warrant Share calculated immediately prior to the time of exercise in accordance with the following formula rounded to the nearest \$0.0001, (as may be adjusted for bonus issues, pro rata issues and reorganisations of capital): $\frac{\$25,000,000}{\text{number of Shares on issue immediately before exercise of the relevant Warrant}}$
Terms of Shares issued	Any Shares issued as a result of exercising a Warrant will be issued on the same terms and rank in all respects on equal terms, with existing Shares.

NB. Adviser Options a will also be issued under this Prospectus.

1.3 Important dates

Event	Date
Settlement of Tranche 1 Placement Shares	31 December 2025
Allotment of Tranche 1 Placement Shares	31 December 2025

Event	Date
Prospectus date	23 March 2026
EGM date for approval of Tranche 2 Placement Shares, Attaching Options and Adviser Options	17 April 2026
Settlement of Tranche 2 Placement Shares	23 April 2026
Allotment of Tranche 2 Placement Shares	24 April 2026
Grant Date of Attaching Options	24 April 2026

All dates and times are subject to change and are indicative only. All times are to Sydney time. The Company, with the consent of the Joint Lead Managers, reserves the right to vary these dates and times without notice. The Company may close the Offers early, withdraw the Offers, or accept late applications.

1.4 Purpose of the Equity Raise and use of funds

The purpose of the Equity Raise is to fully fund the Company's lead CHM CDH17 CAR-T Phase 1/2 clinical trial to the end of Phase 1, support near-term clinical readouts across the portfolio and underpin a comprehensive operational and governance review, as follows:

Use of Placement Share proceeds	\$ million
CHM CDH17 trial	\$3.7
Working Capital and Fund Raising Costs	\$0.7
Total funds raised	\$4.4

Up to approximately a further \$7.3 million may be raised if Attaching Options are exercised. These funds will be applied to the Company's clinical pipeline and working capital.

If the Adviser Options are fully exercised, this will result in additional receipt of \$0.3 million before the expiry of the Adviser Options. This amount, if received, will be applied to the Company's working capital.

1.5 Shareholding structure

The following table shows the shareholding structure of Chimeric on completion of the Equity Raise (assuming that no Existing Options are exercised and that no additional Securities are issued before completion of the Equity Raise):

Shares

Existing Shares on issue as at 23 December 2025 (announcement of the Equity Raise)	4,418,703,619
Approximate number of Placement Shares to be issued under the Placement	1,466,666,665
Approximate total number of Shares on issue after the Equity Raise (before the exercise of any Attaching Options)	5,885,370,284

Options

Existing Options on issue as at 23 December 2025 (announcement of the Equity Raise)	2,119,504,331
Approximate number of Attaching Options to be issued under the Attaching Options Offer	1,466,666,665
Approximate number of Adviser Options to be issued to the Joint Lead Managers under this Prospectus	50,000,000
Maximum number of Options on issue after the Equity Raise	3,636,170,996

Convertible Notes

Existing Convertible Notes on issue as at 23 December 2025 (announcement of the Equity Raise)	Nil
Approximate number of Convertible Notes to be issued under the Convertible Note Offer with an aggregate face value of \$4,000,000	4,000

Warrants

Existing Warrants on issue as at 23 December 2025 (announcement of the Equity Raise)	Nil
Approximate number of Warrants to be issued under the Warrant Offer with an aggregate value of \$2,000,000	2,000

Performance Rights

The Company had 7,227,904 Performance Rights on issue as at 23 December 2025 (announcement of the Equity Raise). No Performance Rights are to be issued under the Offers.

1.6 Potential questions and answers

Question	Answer	Section
Who is the issuer of this Prospectus?	Chimeric Therapeutics Limited ACN 638 835 828	Not applicable
What is the Offer?	The Offer is collectively made up of the: (a) Attaching Options Offer; (b) Adviser Options Offer; (c) Convertible Note Offer; and (d) Warrant Offer.	Section 3.1
What is the Attaching Options Offer?	The Attaching Options Offer is available to Placement Subscribers who have subscribed for New Shares under the Placement. Subject to Shareholder approval at the EGM, the placement subscribers will be issued one Attaching Option for every one Placement Share subscribed for by the Placement Subscribers under the Placement exercisable at \$0.005 each on or before 31 December 2030	Section 3.1

Question	Answer	Section
What is the Convertible Note Offer and Warrant Offer	The Company has entered into a Convertible Notes Agreement and Warrant Deed with a US institutional investor whereby the Company, in accordance with the terms set out in Annexure C and Annexure D, the Company will issue Convertible Notes to the Noteholder. In conjunction with the Convertible Note Agreement, the Company will also issue Warrants to the Noteholder on the terms of the Warrant Deed.	Section 3.1
Are the Offers subject to any conditions?	The issuance of the Attaching Options, Convertible Notes and Warrants pursuant to the Offer is subject to Shareholder approval at the EGM. If the Attaching Options, Convertible Notes and Warrants are not approved at the EGM, they will not be issued. The issuance of the Adviser Options is also subject to Shareholder approval at the EGM.	Section 3.3
When is the EGM?	The EGM is anticipated to be held in April 2026.	Section 3.3
What is the Offer Price of the Attaching Options?	The Attaching Options will be issued for no further consideration and attach to the Placement Shares.	Section 1.1
What rights and liabilities attach to the Attaching Options under the Offer?	The key terms of the Attaching Options include: (a) one Attaching Option will be issued for one Placement Share issued; (b) no issue price is payable for the Attaching Options as they are to be issued together with any application by a Placement Subscriber for Placement Shares; and (c) the exercise price of each Attaching Option is \$0.005, expiring on 31 December 2030. The full details of the rights and liabilities attaching to the Attaching Options are set out in the Annexure A.	Section 8.3 Annexure A
What rights and liabilities attach to the Adviser Options issued under the Offer?	The key terms of the Adviser Options are set out in Annexure B.	Annexure B
What rights and liabilities attach to the Convertible Notes	The key terms of the Convertible Notes are set out in Annexure C.	Annexure C
What rights and liabilities attach to the Warrants	The key terms of the Convertible Notes are set out in Annexure D.	Annexure D

Question	Answer	Section
Will the Attaching Options be listed on ASX?	The Company will not seek official quotation of the Attaching Options offered pursuant to this Prospectus.	Annexure A
Will the Convertible Notes be listed on ASX?	The Company will not seek official quotation of the Convertible Notes offered pursuant to this Prospectus.	Annexure C
Will the Warrants be listed on ASX?	The Company will not seek official quotation of the Warrants offered pursuant to this Prospectus.	Annexure D
What is the Company's financial position?	The Company's financial position is set out in detail in section 5 of this Prospectus.	Section 5
What risks are involved with an investment in the Company?	An investment in Chimeric is subject to both general and specific risks which you should consider before making a decision exercise any Attaching Options.	
	Key specific risks include:	
	Dependence upon licence agreements	Chimeric is reliant on the continuing operation of its key licence agreements. A failure of licensors to comply with the terms of the licence agreements could have a material adverse effect on Chimeric's business, financial condition, operations or prospects.
	Pipeline product in development and not approved for commercial sale	Chimeric's prospects of success are dependent on the success of clinical trials to obtain the regulatory approval for the CAR T technology to be commercialised. Chimeric currently does not have a revenue stream from its product sales and does not expect to generate any such revenue in the short to medium term.
	Clinical trial risk	Chimeric may be unable to secure the necessary approvals to conduct future clinical trials. There is also no assurance that products developed using the CAR T technology will be a success and not expose the company to product liability claims with unforeseen effects on clinical subjects.

Question	Answer		Section
		Unsuccessful clinical trial results could have a significant impact on the value of the Company's securities and the future commercial development of its technology.	
	Regulatory and reimbursement approvals	The research, development, manufacture, marketing and sale of products using the Company's technology are subject to varying degrees of regulation by a number of government authorities in the US, Australia and other countries. Products may also be submitted for reimbursement approval. The availability and timing of that approval may have an impact upon the uptake and profitability of products in some jurisdictions.	
	Commercialisation of products and potential market failure	Chimeric has not yet commercialised its technology and has no current revenue stream. The Company is also dependent on commercially attractive markets remaining available to it during the commercialisation phase and, once developed, to fund sufficient revenues for continued operation.	
	Dependence upon key personnel	Chimeric's key personnel is its primary asset and if any key personnel leave it may be difficult to replace them and may have a negative impact on the Company.	
	Arrangements with third-party collaborators	The Company may collaborate with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of its products. If Chimeric is unable to collaborate with a	

Question	Answer		Section
		third-party it would need to develop and commercialise the CAR T technology at its own expense.	
	Risk of delay and continuity of operations	Chimeric may experience a delay in achieving critical milestones. Any material delays may impact adversely upon the Company, including the timing of any revenues under milestone or sales payments.	
	Competition	Companies in the US and other countries may already be pursuing the development of products that target the same markets that Chimeric is targeting and put them in direct competition with parties who have substantially greater resources than the Company.	
	Requirement to raise additional funds	The Company may be required to raise additional equity or debt capital in the future. As there is no assurance a raise will be successful when required, the Company may need to delay or scale down its operations.	
	Growth	The Company may be unable to manage its future growth successfully and continue to hire and retain the skilled personnel it requires.	
	Manufacturing	Manufacturing processes may lead to disruption, delay or non-supply of product and/or product batches not meeting minimum specifications.	
	Intellectual property	The Company's ability to leverage its innovation and expertise depends on its	

Question	Answer		Section
		ability to continue to protect its intellectual property.	
Is the Placement underwritten?	The Placement is not underwritten.		Section 3.6
Further questions	If you have questions about the Offer, please contact the Share Registry, Boardroom Pty Ltd on 1300 737 760 (inside Australia) or +61 2 9290 9600 (outside Australia).		Section 3.13

1.7 Important notice

This section is not intended to provide full details of the investment opportunity. Read this Prospectus in full to make an informed investment decision. The securities offered under this Prospectus carry no guarantee of return of capital, return on investment, payment of dividends or on the future value of the Shares.

2 Chimeric – the business

2.1 Company overview

Chimeric Therapeutics is an Australian listed (ASX:CHM) clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer by discovering, developing, and commercialising innovative cell therapies with the most curative potential.

Chimeric was founded in 2020 with one asset, CHM CLTX, a first in class Chlorotoxin CAR T cell therapy developed at the prestigious City of Hope Cancer Centre (City of Hope) in Los Angeles, California. The company went public on 18 January 2021 with this single asset being developed in recurrent/ progressive glioblastoma in one phase 1 clinical trial. Five years later the company has three novel assets, four FDA INDs and four clinical trials up and running across the United States. CHM CLTX was mutually agreed to be returned to City of Hope in February 2026 for pipeline optimization.

Cell therapy is considered one of the most promising areas of drug development in oncology today due to the profound responses that patients have had to early CAR T cell therapies. The University of Pennsylvania recently published long term data demonstrating that patients that were treated with early CAR T cell therapies have remained cancer free 20 years later. These demonstrated long term responses have clinicians and scientists now referring to CAR T therapies as curative. It is these types of outcomes that CHM is focused on bringing to more patients with cancer.

In July 2021, Chimeric added a second asset to its pipeline with CHM CDH17, a first in class 3rd generation CDH17 CAR T cell therapy developed at the world-renowned University of Pennsylvania. Scientists at the University of Pennsylvania are widely regarded as leaders in cell therapy development as they were responsible for leading development of the first CAR T cell therapy approved in the United States.

CHM CDH17, targets CDH17 (Cadherin-17), an oncogenic driver of tumour formation and cancer metastasis, most notably in gastrointestinal cancers, Neuroendocrine Tumours and Colorectal cancers. CHM CDH17 has optimised over 10 years of development work at the University of Pennsylvania and showed remarkable preclinical efficacy with complete tumour eradication and no relapse. CHM has dosed the first patients in this Phase 1/2 trial in patients with neuroendocrine tumours, colorectal cancer and gastric cancer. With two clinical trial sites now active and enrolling (Sarah Cannon Cancer Centre in Nashville Tennessee and University of Pennsylvania in Philadelphia, Pennsylvania, Emory in Georgia Atlanta, UChicago in Illinois). Good Manufacturing Practice (GMP) manufacturing has been established with 100% success rate to date; Phase 1 is set to be completed in 2026 calendar year.

In December 2021, Chimeric added a transformational platform technology to its pipeline, securing the exclusive option to CHM 0201, the CORE NK platform. CHM CORE NK Platform is a clinically validated, off the shelf, robust and enhanced natural killer cell platform. The CORE NK platform was developed and clinically validated through a phase 1 clinical trial, which is now complete, at Case Western Reserve University. The trial was a proof-of-concept dose escalation trial with three dose levels, and is now focused on blood cancers; with a recent global IL-2 shortage the trial has been suspended, unrelated to Chimeric's cell therapy.

In partnership with MD Anderson Cancer Centre, Chimeric has commenced a trial to evaluate the synergy of NK cell therapy in combination with the current standard of care for blood cancer, Azacitidine and Venetoclax (aza/ven) in the frontline setting. These trials are supported by Chimeric's partner institutions, with only a minimal financial contribution from Chimeric.

In building and developing a portfolio CHM has also focused strongly on optimising development to minimise timelines to commercialise these therapies for patient access. Optimised development comes about as a direct result of Chimeric's industry leading management team that has extensive experience in cell therapy development and commercialisation. The management team has over 40 years' experience across more than 25 cell therapy development programmes including five of the seven FDA approved CAR T cell therapies.

2.2 Clinical development programme

Chimeric has three current clinical programmes.

Clinical development in cell therapy follows rapid-to-market development paths as evidence by the FDA approval of the seven initial CAR T cell therapies (Yescarta, Kymriah, Abecma, Breyanzi and Tecartus). All seven CAR T therapies have received approval with single arm, Phase 2 registration trials. Chimeric is building clinical development programmes and pathways that would follow this fast-to-market pathway.

- (a) CHM CDH17 is a Phase 1/2 trial currently in the clinic at two sites, having treated the first patient and currently in the second patient manufacturing run. More sites are planned to open in H2 2024.
- (b) CHM CORE-NK has two trials:
 - (i) MD Anderson combination trial in AML (Acute Myeloid Leukemia); and
 - (ii) Case Western University combination trial in AML + Colorectal cancer.

2.3 Intellectual property

Chimeric has completed extensive IP due diligence on all of the assets in its portfolio.

CHM 2101 (CHM CDH17) was granted US patent protection until 2039 with EU patent pending.

CHM 0201 (CHM CORE NK) was granted US patent protection until 2039 with EU patent pending.

2.4 Board and management team

Dr Bradley Glover

Non-Executive Chair & Non-Executive Director

Dr Glover is an executive with over 20 years of leadership experience across global biopharmaceuticals, cell therapy, biomaterials, and life sciences, spanning both public and private companies. Dr Glover brings expertise in cell and gene therapy, corporate development, and capital formation, with a record of executing value-creating strategic transactions, while leading organisations through critical clinical, operational and commercial inflection points. Dr Glover has held senior leadership roles at Kite Pharma, Genentech, Roche, and Imugene, with responsibilities spanning corporate strategy, corporate development, manufacturing expansion, supply chain, and commercial launch execution. Dr Glover also serves on several other boards including Lamorinda Therapeutics and Basilard BioTech.

Dr Lesley Russell

Non-Executive Director

Dr Russell has over 25 years of senior international operational and leadership experience having worked at Amgen, Eli Lilly, Cephalon and Teva Pharmaceuticals. Dr Russell previously served as the Chief Medical Office at Cephalon prior to its acquisition and as the Global Head of R&D at Teva. Dr Russell has extensive knowledge and experience with new drug development along

with CAR T therapies. Dr Russell is currently a Non-Executive Director of Enanta Pharmaceuticals and Imugene Ltd.

Mr Eric Sullivan

Non-Executive Director

Eric Sullivan brings over 20 years of financial and operations experience in the biotechnology industry working on financial management, strategic planning, fundraising and capital market transactions. Mr. Sullivan is currently Chief Financial Officer of Convergent Therapeutics having joined in September 2023. Prior to joining Convergent, he was Chief Financial Officer at TCR2 Therapeutics through the completion of the acquisition by Adaptimmune Therapeutics.

Before that, he was President and Chief Financial Officer at Triplet Therapeutics where he led finance, business development, and corporate operations. Earlier in his career, he held senior management positions at Gemini Therapeutics, Oncorus, bluebird bio, Merrimack Pharmaceuticals, and PwC. Mr. Sullivan holds a B.S. in Accountancy from Bentley University and is a Certified Public Accountant.

Professor H. Miles Prince

Non-Executive Director

Professor Prince is an internationally recognised haematologist and Professor of Medicine at both Melbourne and Monash Universities. He holds the position of Professor and Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare and serves as a Haematologist at the Peter MacCallum Cancer Centre. His extensive experience encompasses clinical practice, groundbreaking research in cancer immunology, stem cell therapies, and leadership in clinical trials involving innovative treatments for blood cancers.

Mr Phillip Hains

Non-Executive Director

The Company outsources its finance and company secretarial requirements to professional corporate services provider Acclime. Mr Hains has been Chief Financial Officer and Joint Company Secretary since 2020, and a director since 2023. Mr. Hains is a Chartered Accountant with over 30 years of extensive experience in roles with a portfolio of ASX and NASDAQ listed companies. He holds a Master of Business Administration from RMIT University and a Public Practice Certificate from the Chartered Accountants Australia and New Zealand.

Mr Nathan Jong

Company Secretary

Mr Jong is a qualified chartered accountant with over 10 years of experience in providing finance and corporate compliance advisory services to a range of businesses including multinational ASX/NASDAQ listed companies. Mr Jong is a senior manager with Acclime.

3 Details and effect of the Offers

3.1 The Offers

This Prospectus contains the following Offers:

(a) **Attaching Options Offer**

This Prospectus invites the Placement Subscribers to apply for a total of up to 1,466,666,665 Attaching Options, on the basis of one Attaching Option for every one Placement Share subscribed for and issued under the Placement.

The issue of Attaching Options is subject to Shareholder approval at the EGM. Only the Placement Subscribers can accept the Attaching Options Offer.

No funds will be raised from the issue of the Attaching Options as the Attaching Options are attaching to the Shares issued/to be issued under the Placement. The Attaching Options offered under this Prospectus will be issued on the terms and conditions, as set out in Annexure A.

(b) **Adviser Options**

In addition, 50 million Adviser Options will be issued to PAC Partners Securities Pty Ltd and Taylor Collison Limited as Joint Lead Managers of the Offers.

(c) **Convertible Note Offer**

The Company shall issue the Convertible Notes with an aggregate face value of \$4,000,000 and a face value of \$1,000 per Convertible Note maturing on the date that is 12 months after the purchase date of the relevant purchase of the Convertible Notes.

The Convertible Notes will be issued under the Convertible Note Offer and will be subject to shareholder approval. An EGM is proposed to be held in April 2026.

The Company does not intend to seek quotation of the Convertible Notes on the ASX. Under the Convertible Note Agreement, the Company is required to apply to ASX for the quotation of the Shares issued on conversion of the Convertible Notes.

The Convertible Notes issued under this Prospectus will be issued on the terms and conditions set out in Annexure C.

(d) **Warrant Offer**

The Company shall issue the Warrants with an aggregate value of \$2,000,000 and a face value of \$1,000 per Warrant and with an exercise price of the Warrant Shares, being \$25,000,000 divided by the number of Shares on issue immediately before the exercise of the Warrants (**Warrant Exercise Price**).

The Warrants are to be issued under the Warrant Offer will be subject to shareholder approval. An EGM is proposed to be held at the end of April 2026.

The Company does not intend to seek quotation of the Warrants on the ASX. Under the Warrant Deed, the Company is required to apply to ASX for quotation of the Shares issued on conversion of the Warrants.

The Warrants offered under this Prospectus will be issued on the terms and conditions, as set out in Annexure D.

The Offers are only available to those who are personally invited to accept the Offers. Accordingly, Application Forms will only be provided by the Company to these parties.

The Attaching Options, Convertible Notes and Warrants issued under this Prospectus will each form a new class of unlisted security of the Company.

All Shares issued on exercise of the Attaching Options, Convertible Note Offer and Warrant Offer will rank equally with the Shares on issue at the date of this Prospectus. Refer to Section 7.2 for further details regarding the rights and liabilities attaching to Shares.

3.2 Purpose of this Prospectus

This Prospectus has been issued to facilitate secondary trading of the Shares to be issued upon exercise of the Attaching Options, Convertible Notes and Warrants to be issued under the Offers. Issuing the Attaching Options, Convertible Notes and Warrants under this Prospectus will enable persons who are issued the Attaching Options, Convertible Notes and Warrants to on-sell the Shares issued on exercise of the Attaching Options pursuant to *ASIC Corporations (Sale Offers That Do Not Need Disclosure) Instrument 2016/80*.

Accordingly, the purpose of this Prospectus is to ensure that the on-sale of the underlying Shares to be issued upon the exercise of the Attaching Options is in accordance with *ASIC Corporations (Sale Offers That Do Not Need Disclosure) Instrument 2016/8*.

3.3 Extraordinary General Meeting

The EGM is anticipated to be held in April 2026 to ask Shareholders to approve the issuance of the:

- (a) Tranche 2 Placement Shares;
- (b) Attaching Options;
- (c) Adviser Options;
- (d) Convertible Notes; and
- (e) Warrants.

At the EGM, Shareholders will also be asked to ratify the issuance of the Tranche 1 Placement Shares.

3.4 Timetable

The indicative timetable for the Offers is set out in Section 1.3.

3.5 Minimum subscriptions

There is no minimum subscription under the Offers.

3.6 Underwriting

The Offers are not underwritten.

3.7 ASX quotation

The Company will not seek official quotation of the Attaching Options offered pursuant to this Prospectus.

3.8 Effect of Equity Raise on control of the Company

The below table sets out the number of Shares, voting power and Options held by the substantial holders of the Company at the date of this Prospectus and after the Equity Raise (based on shares and options to be acquired as set out under section 1.1 with none of the Attaching Options to have been exercised):

Shareholder	At the date of this Prospectus			Following completion of the Equity Raise		
	Shares	Voting power	Options	Shares	Voting power	Options
GKCC LLC	697,478,222	15.8%	387,577,500	1,387,577,500	27.2%	1,387,577,500

The Equity Raise will result in GKCC LLC exceeding 20% voting power in the Company and therefore approval for the Equity Raise will be sought at the EGM for the purpose of item 7 of section 611 of the Corporations Act.

3.9 Financial position

The effect of the Equity Raise (including the Offers) on the financial position of the Company is set out in section 5.

3.10 Taxation considerations

The taxation consequences of an investment in the Company depend upon your particular circumstances. You should make your own enquiries about the taxation consequences of an investment in the Company. If you are in doubt about the course you should follow, you should consult your accountant, stockbroker, solicitor or other professional advisor.

3.11 Foreign selling restrictions

This Prospectus does not constitute an offer of Attaching Options, Convertible Notes or Warrants in any jurisdiction in which it would be unlawful. In particular, this Prospectus may not be distributed to any person, and the Attaching Options, Convertible Notes or Warrants may not be offered or sold, in any country outside Australia except to the extent permitted below.

Hong Kong

WARNING: This Prospectus has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). Accordingly, this Prospectus may not be distributed, and the Attaching Options, Convertible Notes or Warrants may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance).

No advertisement, invitation or document relating to the Attaching Options, Convertible Notes or Warrants has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are

likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the Attaching Options, Convertible Notes or Warrants that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted Attaching Options, Convertible Notes or Warrants may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.

The contents of this Prospectus have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this Prospectus, you should obtain independent professional advice.

New Zealand

This Prospectus has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the "FMC Act").

The Attaching Options, Convertible Notes or Warrants are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who:

- (a) is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- (b) meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- (c) is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- (d) is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- (e) is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

Singapore

This Prospectus and any other materials relating to the Attaching Options, Convertible Notes or Warrants have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this Prospectus and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of the Attaching Options, may not be issued, circulated or distributed, nor may the Attaching Options, Convertible Notes or Warrants be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the "SFA") or another exemption under the SFA.

This Prospectus has been given to you on the basis that you are an "institutional investor" or an "accredited investor" (as such terms are defined in the SFA). If you are not such an investor, please return this Prospectus immediately. You may not forward or circulate this Prospectus to any other person in Singapore.

Any offer is not made to you with a view to the Attaching Options, Convertible Notes or Warrants being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire the Attaching Options, Convertible Notes or Warrants. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.

United States

This Prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The Attaching Options, Convertible Notes or Warrants (including the underlying ordinary shares) have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Attaching Options, Convertible Notes or Warrants may not be offered or sold in the United States except by the Company to the US institutional investors who participated in the Offer and in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

The Attaching Options, Convertible Notes or Warrants will only be offered and sold in the United States to:

- (f) “institutional accredited investors” within the meaning of Rule 501(a)(1), (2), (3), (7), (8), (9) and (12) under the US Securities Act; and
- (g) dealers or other professional fiduciaries organized or incorporated in the United States that are acting for a discretionary or similar account (other than an estate or trust) held for the benefit or account of persons that are not US persons and for which they exercise investment discretion, within the meaning of Rule 902(k)(2)(i) of Regulation S under the US Securities Act.

3.12 Withdrawal

The Company reserves the right to withdraw the Offers, at any time before the allotment of the Attaching Options, Convertible Notes or Warrants.

3.13 Enquiries

If you have questions about the Offers, please contact the share registry, Boardroom Pty Limited, on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia).

4 How to apply

4.1 How to apply

The Offers are only available to those who are personally invited to accept the Offers. Accordingly, Application Forms will only be provided by the Company to these parties.

The Company may determine in its discretion whether to accept any or all Applications.

Completed Application Forms should be delivered to the Company in accordance with the instructions on the Application Form.

4.2 Attaching Options Offer

Applications for Attaching Options under the Attaching Options Offer may only be submitted by the Placement Subscribers (or their nominees).

The Joint Lead Managers have separately advised the Placement Subscribers of the Application procedures for the Attaching Options Offer.

4.3 Lodgement instructions and effect of making an Application

Applications for New Securities must be submitted on an Application Form attached to or accompanying this Prospectus. An Application Form must be completed in accordance with the instructions provided with that Application Form.

An original, completed and lodged Application Form constitutes a binding and irrevocable offer to subscribe for the number of New Securities specified in that Application Form. An Application Form does not need to be signed to be valid. Once an Application has been made, it cannot be revoked.

If an Application Form is not completed correctly, it may be treated by the Company as valid at its discretion. The Directors' decision as to whether to treat such an Application as valid and how to construe, amend or complete a form is final.

4.4 Information Availability

Applicants can obtain a copy of this Prospectus from Chimeric's website at www.chimerictherapeutics.com or by calling the share registry on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) at any time from 8.30 am to 5.00 pm (Sydney time). Shareholders who access the electronic version of this Prospectus should ensure that they download and read the entire Prospectus. The electronic version of this Prospectus will not include an Application Form. A replacement Application Form can be requested by calling the share registry.

5 Financial information

5.1 Historical and pro forma consolidated balance sheet as at 31 December 2025

This section contains a summary of the historical financial information for Chimeric as at 31 December 2025 (**Historical Financial Information**) and a pro-forma historical statement of the financial position as at 31 December 2025 (**Pro Forma Historical Financial Information**) (collectively, **Financial Information**). The Financial Information has been prepared to illustrate the effect of the Equity Raise.

	<i>Pre 31 Dec 2025 component of Equity Raise¹</i>	31 December 2025 Historical	Post 31 Dec 2025 component of Equity Raise	31 December 2025 Pro forma
	\$	\$	\$	\$
ASSETS				
Current assets				
Cash and cash equivalents	1,290,000	2,503,629	6,460,000	8,963,629
Trade and other receivables	-	2,532,595	-	2,532,595
Other current assets	-	88,825	-	88,825
Total current assets	1,290,000	5,125,049	6,460,000	11,585,049
Non-current assets				
Intangible assets	-	804,891	-	804,891
Total non-current assets	-	804,891	-	804,891
Total assets	1,290,000	5,929,940	6,460,000	12,389,940
Current liabilities				
Trade and other payables	-	6,495,078	-	6,495,078
Employee benefit obligations	-	176,217	-	176,217
Other financial liabilities	-	712,232	-	712,232
Total current liabilities	-	7,383,527	-	7,383,527
Non-current liabilities				
Employee benefits obligations	-	1,322	-	1,322
Other financial liabilities	-	1,574,264	-	1,574,264
Total non-current liabilities	-	1,575,586	-	1,575,586
Total liabilities	-	8,959,113	-	8,959,113
Net assets	1,290,000	(3,029,173)	6,460,000	3,430,827
EQUITY				
Share capital	1,400,000	77,478,142	7,000,000	84,478,142
Other reserves	(110,000)	7,042,713	(540,000)	6,502,713
Accumulated losses	-	(87,550,028)	-	(87,550,028)
Total equity	1,290,000	(3,029,173)	6,460,000	3,430,827

1 Pre 31 Dec 2025 component of Equity Raise included in 31 December 2025 Historical Financial Information

5.2 Basis of preparation of financial information

The stated basis of preparation for the Historical Financial Information is in accordance with the recognition and measurement principles of the Australian Accounting Standards.

The stated basis of preparation for the Pro Forma Historical Financial Information is in a manner consistent with the recognition and measurement principles of the Australian Accounting Standards applied to the Historical Financial Information and the events or transactions to which the pro forma adjustments relate, as described in this section of the Prospectus, as if those events or transactions had occurred as at 31 December 2025.

5.3 Pro-forma adjustments to consolidated balance sheet

The Pro Forma Historical Financial Information has been derived from the Historical Financial Information and has been prepared on the basis that the following significant transactions occurred as at 31 December 2025 (noting that 466,666,665 Tranche 1 Shares were issued on 31 December 2025 and are incorporated in the 31 December 2025 Historical Financial Information):

- (a) issue of 309,900,722 Tranche 1 Shares on 7 January 2026;
- (b) issue of 690,099,278 Tranche 2 Shares;
- (c) issue 1,466,666,665 Attaching Options under the Attaching Options Offer (before the exercise of any Attaching Options);
- (d) issue of up to 50 million Adviser Options under the Adviser Option Offer to the Joint Lead Managers (before the exercise of any Adviser Options)²;
- (e) issue of Convertible Notes under the Convertible Note Offer (before the exercise of any Convertible Notes); and
- (f) issue of Warrants under the Warrant Offer (before the exercise of any Warrant).

Due to the nature of the pro forma adjustments, they do not represent the actual or prospective financial position of Chimeric.

5.4 Pro forma cash flow statement as at 31 December 2025

The Company's pro forma historical cash position at 31 December 2025 adjusted for the Equity Raise is derived from actual cash as follows:

	\$
Cash as at 31 December 2025 ³	2,503,629
Gross proceeds of the Equity Raise received after 31 Dec 2025	7,000,000
Offer costs of the Equity Raise paid after 31 Dec 2025	(540,000)
Pro forma historical cash balance	<u>8,963,629</u>

² In the event all Adviser Options are exercised, this will provide an additional \$300,000 to the Company, which will be applied to working capital. Further details on the Adviser Options are summarised in the Joint Lead Managers Mandate in section 7.3 and Annexure B.

³ Includes net proceeds of the Equity Raise received before 31 Dec 2025

6 Risk factors

6.1 Specific investment risks

Dependence upon licence agreements

Access to the intellectual property rights to develop and commercialise CAR T cells in the field of oncology is predicated on the continuing operation of the licence agreements in place between the Company and its licensors. Chimeric is reliant on its licensors to have in place the relevant protection and rights to the technology as well as the authority to enter into the licence agreements. Failure of a licensor or Chimeric to comply with the terms of the licence agreements without an appropriate countermeasure could have a material adverse effect on Chimeric's business, financial condition, operations or prospects. Chimeric is continually assessing the risk and opportunity associated with its business model and licenses to use and develop intellectual property.

Pipeline product in development and not approved for commercial sale

Chimeric's ability to achieve profitability is dependent on a number of factors, including its ability to complete successful clinical trials, obtain regulatory approval for the CAR T technology and successfully commercialise that product. There is no guarantee that Chimeric's product will be commercially successful. Chimeric does not currently generate revenue from product sales and any such revenue is not anticipated in the short to medium term. There are many reasons why initially promising products fail to be successfully commercialised. For example, clinical trials may be suspended for safety or efficacy reasons, following development it may prove difficult or impossible to manufacture the products on a large scale, or, during the period of development, competitors (including those with greater resources) may emerge with competing or alternative treatments.

Clinical trial risk

The Company may be unable to secure necessary approvals from regulatory agencies and institutional bodies (clinics and hospitals) to conduct future clinical trials. There is also no assurance that products developed using the Company's technology will prove to be safe and efficacious in clinical trials, or that the regulatory approval to manufacture and market its products will be received. Clinical trials might also potentially expose the Company to product liability claims in the event its products in development have unexpected effects on clinical subjects. Clinical trials undertaken by the Company have many associated risks which may impact the Company's profitability and future productions and commercial potential. They may prove unsuccessful or non efficacious, impracticable or costly. The clinical trials could be terminated which will likely have a significant adverse affect on the Company, the value of its securities and the future commercial development of its technology.

Regulatory and reimbursement approvals

The research, development, manufacture, marketing and sale of products using the Company's technology are subject to varying degrees of regulation by a number of government authorities in Australia and overseas. Products developed using the Company's technology must undergo a comprehensive and highly regulated development and review process before receiving approval for marketing. The process includes the provision of clinical data relating to the quality, safety and efficacy of the products for their proposed use. Products may also be submitted for reimbursement approval. The availability and timing of that reimbursement approval may have an impact upon the uptake and profitability of products in some jurisdictions. Furthermore, any of the products utilising the Company's technology may be shown to be unsafe, non-efficacious,

difficult or impossible to manufacture on a large scale, uneconomical to market, compete with superior products marketed by third parties or not be as attractive as alternative treatments.

Commercialisation of products and potential market failure

The Company has not yet commercialised its technology and as yet has no revenues. The Company is also dependent on commercially attractive markets remaining available to it during the commercialisation phase and there is a risk that, once developed and ready for sale, commercial sales, to fund sufficient revenues for continued operations and growth, may not be achieved.

Dependence upon key personnel

Chimeric depends on the talent and experience of its personnel as its primary asset. There may be a negative impact on Chimeric if any of its key personnel leave. It may be difficult to replace them, or to do so in a timely manner or at comparable expense. Additionally, any key personnel of the Company who leave to work for a competitor may adversely impact the Company.

Arrangements with third-party collaborators

Chimeric may pursue collaborative arrangements with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of its products. These collaborators may be asked to assist with funding or performing clinical trials, manufacturing, regulatory approvals or product marketing. There is no assurance that the CAR T technology will attract and retain appropriate strategic partners or that any such collaborators will perform and meet commercialisation goals. If Chimeric is unable to find a partner, it would be required to develop and commercialise the CAR T technology at its own expense. This may place significant demands on the Company's internal resources and potentially delay the commercialisation of the technology.

Risk of delay and continuity of operations

Chimeric may experience delay in achieving a number of critical milestones, including securing commercial partners, completion of clinical trials, obtaining regulatory approvals, manufacturing, product launch and sales. Any material delays may impact adversely upon the Company, including the timing of any revenues under milestone or sales payments.

Competition

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. A number of companies, both in Australia and abroad, may be pursuing the development of products that target the same markets that Chimeric is targeting. The Company's products may compete with existing alternative treatments that are already available to customers. In addition, a number of companies, both in Australia and abroad, may be pursuing the development of products that target the same conditions that the Company is targeting. Some of these companies may have, or develop, technologies superior to the Company's own technology. The Company may face competition from parties who have substantially greater resources than the Company.

Requirement to raise additional funds

Whilst the Directors believe that the funds raised through the Offers may be sufficient for the Company's short-term objectives, the Company is likely to require substantial additional financing in the future to sufficiently fund its operations, research and development. The Company's actual cash requirements may vary from those now planned and will depend upon many factors, including:

- (a) the continued progress of its research and development programmes;
- (b) the timing, costs and results of clinical trials;
- (c) the cost, timing and outcome of submissions for regulatory approval; and
- (d) the status and timing of competitive developments.

Without revenue from commercialisation, the Company may be required to raise additional equity or debt capital in the future. There is no assurance that it will be able to raise that capital when it is required or, even if available, the terms may be unsatisfactory. If the Company is unsuccessful in obtaining funds when they are required, the Company may need to delay or scale down its operations.

Growth

There is a risk that the Company may be unable to manage its future growth successfully. The ability to hire and retain skilled personnel as outlined above may be a significant obstacle to growth.

Manufacturing

Manufacturing processes may result in product batches not meeting minimum specifications, raw material components not being sourced to specification. The manufacturing process may encounter process issues not previously identified and controlled, and there may be non-controllable disruptions to the operations of the products, contract manufacturers. These factors may lead to delay or non-supply of product and/or adverse regulatory outcomes.

The Company mitigates this risk by working very closely with its suppliers to ensure scheduling fits forecast requirements and that the manufacturing processes are actively managed. New suppliers are subject to due diligence processes and key relationships are developed with regulatory agencies to support the Group in the event of supply chain disruption.

Intellectual property

The Company's ability to leverage its innovation and expertise depends upon its ability to protect its intellectual property and any improvements to it. The intellectual property may not be capable of being legally protected, it may be the subject of unauthorised disclosure or be unlawfully infringed, or the Company may incur substantial costs in asserting or defending its intellectual property rights. This includes the Company's ability to obtain commercially valuable patent claims.

The Company's patent applications are still pending, and additional patent applications may need to be filed to provide more extensive intellectual property protection. Examination of patents may be expensive and time-consuming, with no guarantee that lodged patent applications will result in granted patents. It may also take longer than expected for patents to be granted and, even if successful, the claims of any patents that are granted may not provide meaningful protection.

Although the Company has itself conducted patent searches on publicly available databases, there are limitations on searching. Searches are dependent on the accuracy and effectiveness of the searching method used and the accuracy and scope of the records held. No search can ever be entirely inclusive or exhaustive because some forms of disclosure such as prior public use, oral disclosure, prior commercial exploitation or prior publication in non-patent literature cannot be searched systematically.

If patents are not granted to Chimeric, then the value of the Company's intellectual property rights may be significantly diminished. Further, any information contained in patent applications will become part of the public domain, and so will not be protected as confidential information.

6.2 General investment risks

Share market investments

It is important to recognise that the Shares are quoted on ASX and their price might rise or fall and they might trade at prices below or above the offer price.

Factors affecting the price at which the Shares are traded on ASX could include domestic and international economic conditions. In addition, the prices of many listed entities' securities are affected by factors that might be unrelated to the operating performance of the relevant company. Those fluctuations might adversely affect the price of the Shares.

General economic conditions

Chimeric's operating and financial performance is influenced by a variety of general economic and business conditions including the level of inflation, interest rates and government fiscal, monetary and regulatory policies. Prolonged deterioration in general economic conditions, including an increase in interest rates, could be expected to have a corresponding adverse impact on the Company's operating and financial performance.

Accounting standards

Australian accounting standards are set by the AASB and are outside the Directors' and Chimeric's control. Changes to accounting standards issued by AASB could materially adversely affect the financial performance and position reported in Chimeric's financial statements.

Tax risks

Changes to the rate of taxes imposed on Chimeric (including in overseas jurisdictions in which Chimeric operates now or in the future) or tax legislation generally may affect Chimeric and its Shareholders. In addition, an interpretation of Australian tax laws by the Australian Taxation Office that differs to Chimeric's interpretation may lead to an increase in Chimeric's tax liabilities and a reduction in Shareholder returns.

Personal tax liabilities are the responsibility of each individual investor. Chimeric is not responsible either for tax or tax penalties incurred by investors.

Litigation

There is a risk that the Company may in future be the subject of or required to commence litigation. There is, however, no litigation, mediation, conciliation or administrative proceeding taking place, pending or threatened against the Company.

6.3 Cautionary statement

Statements in this Prospectus may be forward looking statements.

Forward looking statements can be identified by the use of forward-looking terminology such as, but not limited to, 'may', 'will', 'expect', 'anticipate', 'estimate', 'would be', 'believe', or 'continue' or the negative or other variations of comparable terminology. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. The Directors' expectations, beliefs and projections are expressed in good faith and are believed

to have a reasonable basis. They are based on, among other sources, the examination of historical operating trends, data in the Company's records and other data available from third parties. There can be no assurance, however, that the Directors' expectations, beliefs or projections will give the results projected in the forward-looking statements. Investors should not place undue reliance on these forward-looking statements.

Additional factors that could cause actual results to differ materially from those indicated in the forward-looking statements are discussed earlier in this section.

7 Material agreements

7.1 Key documents

The Board considers that certain agreements relating to Chimeric are significant to the Offers, the operations of Chimeric or may be relevant to investors. A description of material agreements or arrangements, together with a summary of the more important details of each of these agreements is set out below.

7.2 Constitution

Below is a summary of the key provisions of Chimeric's Constitution. This summary is not exhaustive, nor does it constitute a definitive statement of a Shareholder's rights and obligations.

Shares

The Directors are entitled to issue and cancel Shares in the capital of Chimeric, grant Options over unissued shares and settle the manner in which fractions of a Share are to be dealt with. The Directors may decide the persons to whom, and the terms on which, Shares are issued or Options are granted as well as the rights and restrictions that attach to those Shares or Options.

The Constitution also permits the issue of preference shares on terms determined by the Directors.

Chimeric may also sell a Share that is part of an unmarketable parcel of shares under the procedure set out in the Constitution.

Variation of class rights

The rights attached to any class of Shares may, unless their terms of issue state otherwise, only be varied with the consent in writing of members holding at least three-quarters of the Shares of that class, or with the sanction of a special resolution passed at a separate meeting of the holders of Shares of that class.

Restricted securities

If the ASX classifies any of Chimeric's share capital as restricted securities, then the restricted securities must not be disposed of during the escrow period and Chimeric must refuse to acknowledge a disposal of the restricted securities during the escrow period, except as permitted under the Listing Rules or by the ASX.

Share certificates

Subject to the requirements of the Corporations Act, the Listing Rules or the ASX Settlement Operating Rules, Chimeric need not issue share certificates if the Directors so decide.

Calls

The Directors may, from time to time, call upon Shareholders for unpaid monies on their shares. The Directors must give Shareholders notice of a call at least 30 business days before the amount called is due, specifying the time and place of payment. If a call is made, Shareholders are liable to pay the amount of each call by the time and at the place specified.

A call is taken to have been made when a Directors' resolution passing the call is made or on any later date fixed by the Board. A call may be revoked or postponed at the discretion of the Directors.

Forfeiture and lien

Chimeric may forfeit Shares to cover any call, or other amount payable in respect of Shares, which remains unpaid following any notice to that effect sent to a Shareholder. Forfeited Shares become the property of Chimeric and the Directors may sell, reissue or otherwise dispose of the Shares as they think fit.

A person whose Shares have been forfeited may still be required to pay Chimeric all calls and other amounts owing in respect of the forfeited Shares (including interest) if the Directors so determine.

Chimeric has a first and paramount lien for unpaid calls, instalments and related interest and any amount it is legally required to pay in relation to a Shareholder's Shares. The lien extends to all distributions relating to the Shares, including dividends.

Chimeric's lien over Shares will be released if it registers a transfer of the Shares without giving the transferee notice of its claim.

Share transfers

Shares may be transferred by any method permitted by the Corporations Act, the Listing Rules or the ASX Settlement Operating Rules or by a written transfer in any usual form or in any other form approved by the Directors. The Directors may refuse to register a transfer of Shares where it is not in registrable form, Chimeric has a lien over any of the Shares to be transferred or where it is permitted to do so by the Listing Rules or the ASX Settlement Operating Rules.

General meetings

Each Shareholder, Director and auditor is entitled to receive notice of and attend any general meeting of Chimeric. Two Shareholders must be present to constitute a quorum for a general meeting and no business may be transacted at any meeting except the election of a chair and the adjournment of the meeting, unless a quorum is present when the meeting proceeds to business.

Voting rights

Subject to any rights or restrictions attached to any Shares or class of shares, on a show of hands each Shareholder present has one vote and, on a poll, one vote for each fully paid Share held, and for each partly paid Share, a fraction of a vote equivalent to the proportion to which the Share has been paid up. Voting may be in person or by proxy, attorney or representative.

Remuneration of Directors

Each Director is entitled to remuneration from Chimeric for his or her services as decided by the Directors but the total amount provided to all Directors for their services as Directors must not exceed in aggregate in any financial year the amount fixed by Chimeric in general meeting. The remuneration of an executive Director must not include a commission on, or a percentage of, profits or operating revenue.

Remuneration may be provided in the manner that the Directors decide, including by way of non-cash benefits. There is also provision for Directors to be paid extra remuneration (as determined by the Directors) if they devote special attention to the business of Chimeric or otherwise perform

services which are regarded as being outside of their ordinary duties as Directors or, at the request of the Directors, engage in any journey on Chimeric's business.

Directors are also entitled to be paid all travelling and other expenses they incur in attending to Chimeric's affairs, including attending and returning from general meetings or Board meetings, or meetings of any committee engaged in Chimeric's business.

Interests of Directors

A Director who has a material personal interest in a matter that is being considered by the Board must not be present at a meeting while the matter is being considered nor vote on the matter, unless the Corporations Act allows otherwise.

Election and retirement of Directors

There must be a minimum of three Directors and a maximum of 12 Directors unless Chimeric in general meeting resolves otherwise.

Where required by the Corporations Act or Listing Rules, Chimeric must hold an election of directors each year. No Director, other than the managing director, may hold office without re-election beyond the third annual general meeting following the meeting at which the Director was last elected or re-elected. A Director appointed to fill a casual vacancy, who is not a managing Director, holds office until the conclusion of the next annual general meeting following his or her appointment. If there would otherwise not be a vacancy, and no Director is required to retire, then the director who has been longest in office since last being elected must retire.

If a number of Directors were elected on the same day, the Directors to retire is (in default of agreement between them) determined by ballot.

Dividends

If the Directors determine that a final or interim dividend is payable, it is (subject to the terms of issue on any Shares or class of Shares) paid on all Shares proportionate to the amount for the time being paid on each Share. Dividends may be paid by cash, electronic transfer or any other method as the Board determines.

The Directors have the power to capitalise and distribute the whole or part of the amount from time to time standing to the credit of any reserve account or otherwise available for distribution to Shareholders. The capitalisation and distribution must be in the same proportions which the Shareholders would be entitled to receive if distributed by way of a dividend.

Subject to the Listing Rules, the Directors may pay a dividend out of any fund or reserve or out of profits derived from any source.

Proportional takeover bids

Chimeric may prohibit registration of transfers purporting to accept an offer made under a proportionate takeover bid unless a resolution of Chimeric has been passed approving the proportional takeover bid under the provisions of the Constitution.

The rules in the Constitution relating to proportional takeover bids cease on the third anniversary of the adoption of the Constitution, or the renewal of the rules, unless renewed by a special resolution of Shareholders.

Indemnities and insurance

Chimeric must indemnify current and past Directors and other executive officers (**Officers**) of Chimeric on a full indemnity basis and to the fullest extent permitted by law against all liabilities incurred by the Officer as a result of their holding office in Chimeric or a related body corporate.

Chimeric may also, to the extent permitted by law, purchase and maintain insurance, or pay or agree to pay a premium for insurance, for each Officer against any liability incurred by the Officer as a result of their holding office in Chimeric or a related body corporate.

7.3 Joint lead manager mandate

The Company has engaged PAC Partners Securities Pty Ltd (**PAC Partners**) and Taylor Collison Limited (**Taylor Collison**) as Joint Lead Managers for the Offers pursuant to the terms of the Joint Lead Manager Mandate for each of PAC Partners and Taylor Collison.

The Joint Lead Managers will receive the following fees for its joint lead manager and offer management services:

- (a) Equity Raise Management Fee: 3.0% of the Offer Proceeds.
- (b) Equity Raise Selling Fee: 3.0% of the Offer Proceeds.
- (c) Adviser Options: 50,000,000 Adviser Options. The Adviser Options will have an exercise price of \$0.006 per Adviser Option, an expiry date of 31 March 2029 and shall otherwise be on the terms set out in Annexure B.

The Joint Lead Manager Mandates otherwise contains terms and conditions considered standard for an agreement of this type.

7.4 Documents available for inspection

Copies of the following documents are available for inspection during normal office hours at the registered office of the Company for 13 months after the date of this Prospectus:

- (a) the constitution of Chimeric; and
- (b) the consents to the issue of this Prospectus.

8 Additional information

8.1 Principal effect of the Offers on the Company

The principal effects of the Offers will be to:

- (a) increase the number of Options on issue from 2,119,504,331 Options to 3,636,170,996 Options;
- (b) increase the number of Convertible Notes on issue from nil to 4,000; and
- (c) increase the number of Warrants on issue from nil to 2,000.

8.2 Continuous reporting and disclosure obligations

This Prospectus is a 'transaction specific prospectus' issued under section 713 Corporations Act as a prospectus for the issue of options to acquire continuously quoted securities.

In general terms, a transaction specific prospectus is only required to contain information about the effect of the issue of securities on a company and the rights attaching to the securities. It is not necessary to include general information about all of the assets and liabilities, financial position, profits and losses or prospects of the issuing company.

The Company is subject to regular reporting and disclosure obligations because it is a 'disclosing entity' for the purposes of the Corporations Act. Additionally, as a listed company, Chimeric is subject to the Listing Rules which require disclosure to ASX of any information the Company has which a reasonable person would expect to have a material effect on the price or value of its Shares.

Copies of ASX announcements are available on the ASX website or the Company's website at www.chimerictherapeutics.com.

The Company's ASX announcements since 29 August 2025 to the date of this Prospectus are set out below.

Date	Announcements
29/08/2025	Corporate Governance Statement and Appendix 4G
09/09/2025	Presentation to investor webinar
29/09/2025	Disease control and tumour shrinkage observed in CHM CDH17
02/10/2025	Additional complete responses in CHM CORE-NK Phase 1b trial
03/10/2025	Investor update webinar - 11am AEDT, Wednesday 8 Oct
08/10/2025	Presentation to investor webinar
10/10/2025	Application for quotation of securities - CHM
10/10/2025	Notification regarding unquoted securities - CHM
10/10/2025	Becoming a substantial holder
27/10/2025	Notice of Annual General Meeting/Proxy Form
31/10/2025	Quarterly Activities/Appendix 4C Cash Flow Report
06/11/2025	Response to ASX Query Letter

Date	Announcements
13/11/2025	Pause in Trading
13/11/2025	CHM CORE NK Combination Phase 1b trial update
13/11/2025	75% disease control observed in CHM CDH17 trial
24/11/2025	Chimeric received \$4.5m R&D Tax Incentive
25/11/2025	Presentation to AGM
25/11/2025	Results of Meeting
26/11/2025	Final Director's Interest Notice – PH
28/11/2025	Company update-board changes, shareholder feedback & support
08/12/2025	CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
19/12/2025	Trading Halt
19/12/2025	Change of Director's Interest Notice - MP
19/12/2025	Notification regarding unquoted securities - CHM
23/12/2025	\$8.4 M funding to drive CHM CDH17 and resignation of CMO
23/12/2025	Proposed issue of securities – CHM
23/12/2025	Proposed issue of securities – CHM
31/12/2025	Application for quotation of securities – CHM
31/12/2025	Notice under section 708A
05/01/2026	Ceasing to be a substantial holder
07/01/2026	Application for quotation of securities – CHM
07/01/2026	Notice under section 708A
09/01/2026	Change in substantial holding
28/01/2026	Quarterly Activities/ Appendix 4C Cash Flow Report
12/02/2026	CHM CDH17 advances to Dose Level 3
16/02/2026	Board and management update
16/02/2026	Initial Director's Interest Notice (BG)
25/02/2026	Funding and EGM update
25/02/2026	Update – Proposed issue of securities CHM
25/02/2026	Proposed issue of securities – CHM
25/02/2026	Revised response to ASX query letter
27/02/2026	Portfolio streamlined – return of CHM CLTX to City of Hope
27/02/2026	Half year report and appendix 4D 31 December 2025
02/03/2026	Chimeric receives \$1.8m advance on FY26 R&D tax incentive
06/03/2026	Letter to Shareholders
19/03/2026	Notice of Extraordinary General Meeting/Proxy Form
19/03/2026	Consolidation/Split - CHM

Date	Announcements
19/03/2026	Update - Proposed issue of securities - CHM

In addition, copies of documents lodged with ASIC in relation to the Company may be obtained from, or inspected at, an office of ASIC.

The information in the Annual Report and the ASX announcements described in the table above may be of interest to investors and their financial advisers as these documents contain information regarding the Company's financial position and operations that investors may consider relevant to any decision to apply for Attaching Options, Convertible Notes or Warrants under the Offers.

The Directors rely upon section 712(3) Corporations Act with the inclusion by reference of:

- (a) the Annual Report; and
 - (b) the Company's ASX announcements since 29 August 2025 set out in the table above,
- for the purposes of section 711 Corporations Act.

8.3 Rights attaching to Attaching Options

The rights attaching to the Attaching Options are summarised in the Annexure A to this Prospectus.

8.4 Rights attaching to Adviser Options

The rights attaching to the Adviser Options are summarised in section 7.3 and Annexure B.

8.5 Rights attaching to the Convertible Notes

The rights attaching to the Convertible Notes are summarised in Annexure C.

8.6 Rights attaching to the Warrants

The rights attaching to the Warrants are summarised in Annexure D.

8.7 Existing Options

ASX security code and description	Total number of securities on issue
CHMAY: OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	303,254,331
CHMAAG: OPTION EXPIRING 31-MAR-2026 EX \$0.004	1,791,250,000
CHMAAH: OPTION EXPIRING 10-OCT-2028 EX \$0.008	25,000,000

The Board considers it is unlikely that any Existing Options will be exercised in the immediately foreseeable future. However, if any Existing Options are exercised including prior to the expiry of this Prospectus, any proceeds raised will be applied to the general working capital of Chimeric.

8.8 Litigation

To the best of the Directors' knowledge and belief, no litigation, mediation, conciliation or administrative proceeding is taking place, pending or threatened against the Company.

8.9 Consents and disclaimers of responsibility

None of the parties referred to below has made any statement that is included in this Prospectus or any statement on which a statement made in this Prospectus is based, except as specified below. Each of the parties referred to below, to the maximum extent permitted by law, expressly disclaims, and takes no responsibility for, any part of this Prospectus, other than the reference to its name and the statement included in this Prospectus with the consent of that party, as specified below.

PAC Partners has given, and has not withdrawn, its written consent to be named as Joint Lead Manager to the Offers in the form and context in which it is named.

Taylor Collison has given, and has not withdrawn, its written consent to be named as Joint Lead Manager to the Offers in the form and context in which it is named.

McCullough Robertson has given, and has not withdrawn, its written consent to be named as lawyers to the Company in the form and context in which it is named.

Boardroom Pty Ltd has given, and not withdrawn, its written consent to be named as share registrar in the form and context in which it is named.

8.10 Interests of Joint Lead Managers

Other than as set out elsewhere in this Prospectus:

- (a) the Joint Lead Managers have not, and have not had in the two years before lodgement of this Prospectus, any interest in:
 - (i) the formation or promotion of Chimeric;
 - (ii) the offer of the Attaching Options, Convertible Notes or Warrants; or
 - (iii) any property proposed to be acquired by Chimeric in connection with the formation or promotion of Chimeric or the offer of the Attaching Options, Convertible Notes or Warrants; and
- (b) no amounts have been paid or agreed to be paid and no benefit has been given or agreed to be given, to the Joint Lead Managers for services rendered by it in connection with the formation or promotion of Chimeric or the offer of the Attaching Options, Convertible Notes or Warrants.

8.11 Interests of experts and advisors

Except as set out in this Prospectus:

- (a) no person named in this Prospectus as performing a function in a professional, advisory or other capacity in connection with the preparation or distribution of this Prospectus has any interest or has had any interest during the last two years:
 - (i) in the formation or promotion of Chimeric;
 - (ii) in property acquired or proposed to be acquired by Chimeric in connection with its formation or promotion or the offer of the Attaching Options, Convertible Notes or Warrants; or
 - (iii) the offer of the Attaching Options, Convertible Notes or Warrants; and
- (b) no amount has been paid or agreed to be paid, and no benefit has been given, or agreed to be given, to any person named in this Prospectus as performing a function in a professional, advisory or other capacity in connection with the preparation or distribution of this Prospectus in connection with the services provided by the person in connection with the:
 - (i) formation or promotion of Chimeric, or
 - (ii) offer of the Attaching Options, Convertible Notes or Warrants.

PAC Partners and Taylor Collison have acted as Joint Lead Managers to the Offers. PAC Partners and Taylor Collison will be paid a management and selling fee, details of which are disclosed in section 7.3 of this Prospectus.

McCullough Robertson has acted as legal advisor to the Company for the Offers and has undertaken due diligence enquiries and provided legal advice on the Offers. McCullough Robertson will be paid an amount of \$50,000 for these services.

8.12 Interests of Directors

Other than as set out above or elsewhere in this Prospectus:

- (a) no Director or proposed Director of Chimeric has, or has had in the two years before lodgement of this Prospectus, any interest in:
 - (i) the formation or promotion of Chimeric;
 - (ii) any property acquired or proposed to be acquired by Chimeric in connection with the formation or promotion or the offer of the Attaching Options, Convertible Notes or Warrants; or
 - (iii) the offer of the Attaching Options, Convertible Notes or Warrants; and
- (b) no amounts have been paid or agreed to be paid and no benefit has been given or agreed to be given, to any Director or proposed Director of Chimeric either:
 - (i) to induce him or her to become, or to qualify him or her as, a Director, or
 - (ii) otherwise for services rendered by him or her in connection with the formation or promotion of Chimeric or the offer of the Attaching Options, Convertible Note or Warrants.

Shareholdings

The Directors or their associates have a beneficial interest in the following Existing Shares and Existing Options at the date of this Prospectus:

Director	Shareholder	Existing Shares	Existing Options
Dr Bradley Glover	n/a	nil	nil
Mr Phillip Hains	Mr Phillip Hains and associates	12,934,724	2,608,696
Prof. Miles Prince	Prof. Miles Prince and associates	4,273,142	16,667,000
Dr Lesley Russell	Dr Lesley Russell	1,739,130	nil
Mr Eric Sullivan	Mr Eric Sullivan	nil	2,750,000

The Directors have not subscribed for Attaching Options under the Attaching Option Offer.

Payments to Directors

The constitution of Chimeric provides that the Directors may be paid, as remuneration for their services, a sum set from time to time by the Shareholders in general meeting, with that sum to be divided among the Directors as they agree.

The maximum aggregate amount which has been approved by the Shareholders for payment to the Directors is \$500,000 per annum. The current fees are \$100,000 per annum for the Non-Executive Chairman and \$50,000 per annum for each of the Non-Executive Directors.

8.13 Taxation implications

The Directors do not consider that it is appropriate to give potential Applicants advice regarding the taxation consequences of applying for the Attaching Options, Convertible Note or Warrants under this Prospectus, as it is not possible to provide a comprehensive summary of the possible taxation positions for potential Applicants.

Neither the Company nor any of its advisors or officers accept any responsibility or liability for any taxation consequences to potential Applicants in relation to the Offers. Potential Applicants should, therefore, consult their own tax adviser in connection with the taxation implications of the Offers.

8.14 Electronic Prospectus

This Prospectus is available in electronic form at www.chimerictherapeutics.com. Any person receiving this Prospectus electronically will, on request, be sent a paper copy of the Prospectus by Chimeric free of charge.

The Application Form may only be distributed attached to a complete and unaltered copy of the Prospectus. The Application Form included with this Prospectus contains a declaration that the investor has personally received the complete and unaltered Prospectus before completing the Application Form.

Chimeric will not accept a completed Application Form if it has reason to believe that the Applicant has not received a complete paper copy or electronic copy of the Prospectus or if it has reason to believe that the Application Form or electronic copy of the Prospectus has been altered in any way.

While Chimeric believes that it is extremely unlikely that during the period of the Offers the electronic version of the Prospectus will be altered in any way, Chimeric cannot give any absolute assurance that this will not occur. Any investor in doubt about the validity or integrity of an electronic copy of the Prospectus should immediately request a paper copy of the Prospectus directly from Chimeric or a financial advisor.

8.15 Privacy

Eligible Shareholders may be asked to give personal information to Chimeric directly, and through the share registry, such as name, address, telephone and fax numbers, tax file number and account details. The Company and the share registry collect, hold and use that personal information to provide facilities and services to eligible Shareholders and undertake administration. Access to information may be disclosed by the Company to its agents and service providers on the basis that they deal with the information under the *Privacy Act 1988* (Cth). The Company's privacy policy sets out how Shareholders may request access to and correction of their personal information held by or on behalf of the Company (by contacting the share registry), how Shareholders can complain about privacy related matters and how the Company responds to complaints.

8.16 Costs of the Offer

The total estimated expenses of the Offers of \$650,000 will be paid by the Company from its cash reserves.

8.17 Authorisation

This Prospectus is issued by the Company. Each Director has consented to the lodgement of the Prospectus with ASIC.

Dated 23 March 2026



Dr Bradley Glover

Chair and Non-Executive Director

9 Glossary

In this document:

Actual Trading Day	means a Trading Day on which trading actually takes place in Shares on the ASX.
Adviser Options	means new Options in the Company offered to the Joint Lead Managers under this Prospectus as summarised in section 7.3 and Annexure B.
Annual Report	means the annual report of the Company for the financial year ended 30 June 2025 which includes audited financial statements for the financial year ended 30 June 2025 and the auditor's report, which was lodged with ASX and ASIC on 29 August 2025.
Applicant	means a person who applies for Attaching Options under and in accordance with this Prospectus.
Application	means a valid application for Attaching Options offered under this Prospectus.
Application Form	means the application form that accompanies this Prospectus.
ASIC	means the Australian Securities and Investments Commission.
ASX	means ASX Limited ACN 008 624 691 or the securities exchange operated by it (as the case requires).
Attaching Options	has the meaning given in section 1.1.
Attaching Options Offer	means the issue of one Attaching Option for every one Placement Share subscribed for by the Placement Subscribers under the Placement.
Board	means the board of directors of the Company.
Business Day	means a business day as defined in the Listing Rules.
CHESS	means Clearing House Electronic Subregister System, operated by ASX Settlement.
Company or Chimeric	means Chimeric Therapeutics Limited ACN 638 835 828.
Convertible Note	means the convertible notes offered by the Company under this Prospectus with a face value of \$1,000, to be exercised before the convertible note maturity date, being 12 months after the purchase of the relevant convertible note.
Convertible Note Agreement	means the agreement between the Company and the Noteholder for the issue of Convertible Notes.
Convertible Note Offer	means the issue of Convertible Notes to the Noteholder with a face value of \$1,000 and a maturity date which is the date that is 12 months after the purchase of the Convertible Notes.
Conversion Notice Date	means the date that the Noteholder, at its discretion, converts one or more Convertible Note then on issue, by providing the Company notice in accordance with the Convertible Note Agreement.
Conversion Shares	means Shares issued in respect of a conversion under the Convertible Note Agreement.

Corporations Act	means <i>Corporations Act 2001</i> (Cth).
Directors	means the directors of the Company.
EGM or Meeting	means the extraordinary general meeting to be held by the Company in April 2026.
Equity Raise	means the equity raise described in section 1.1 of this Prospectus.
Existing Options	means the Options already on issue in Chimeric and referred to in section 8.4 of this Prospectus.
Existing Shares	means the Shares already on the date of this Prospectus.
Grant Date	means the date the Attaching Options are granted to Placement Subscribers which, as at the date of this Prospectus, is expected to be following the EGM in April 2026.
Joint Lead Manager Mandate	means the joint lead manager mandate letter between the Company and the Joint Lead Managers dated on or about 27 October 2025.
Joint Lead Managers	means PAC Partners and Taylor Collison.
Listing Rules	means the Listing Rules of ASX and any other rules of ASX which are applicable while the Company is admitted to the Official List of ASX, each as amended or replaced from time to time, except to the extent of any express written waiver by ASX.
New Securities	means the Securities offered under this Prospectus, being any one or more of the following, as the context requires: a. Attaching Options under the Attaching Options Offer; b. Convertible Notes under the Convertible Note Offer; and c. Warrants under the Warrant Offer.
Noteholder	means the holder of the Convertible Notes and Warrants under the terms of the Convertible Note Agreement and the Warrant Deed.
Offers	means the: a. Attaching Options Offer; b. Convertible Note Offer; and c. Warrant Offer, (each an Offer , as the context requires).
Option	means an option to subscribe for a Share.
PAC Partners	PAC Partners Securities Pty Ltd ACN 623 653 912.
Placement	means has the meaning given to that term in section 1.1(a).
Placement Shares	means the term defined in section 1.1 of this Prospectus.
Placement Subscriber	means sophisticated and professional investors to whom Placement Shares are to be issued under the Placement.
Prospectus	means this document, including the Application Form.
Securities	means has the meaning given to that term in section 761A of the Corporations Act and includes a Share and an Option.
Share Registry	means Boardroom Pty Limited.

Shareholders	means a person who is the registered holder of Shares.
Shares	means fully paid ordinary shares in Chimeric.
Taylor Collison	means Taylor Collison Limited ACN 008 172 450.
Tranche 1	has the meaning given in section 1.1(a)(i).
Tranche 2	has the meaning given in section 1.1(a)(ii).
Us or we	means the Company.
Warrant	means the warrants issued under the Warrant Deed.
Warrant Deed	means the warrant deed between Chimeric and the Noteholder.
Warrant Offer	means the issue of Warrants to the Noteholder with an exercise price of \$25,000,000 divided by the number of Shares on issue immediately before the exercise of the relevant Warrant.
Warrant Shares	means any Shares issued upon the exercise of Warrants in accordance with the Warrant Deed.
You	means the investors under this Prospectus.

Corporate directory

Company

Chimeric Therapeutics Limited ACN 638 835 828
Suite 1, Level 3, 62 Lygon Street
Carlton South, VIC 3053
www.chimerictherapeutics.com

Directors

Dr Bradley Glover – Chair and Non-Executive Director
Dr Lesley Russell – Non-Executive Director
Mr Phillip Hains – Non-Executive Director
Mr Eric Sullivan – Non-Executive Director
Professor Henry Miles Prince – Non-Executive Director

Company Secretary

Mr Nathan Jong

Share Registry

Boardroom Pty Limited
Level 8, 210 George Street
Sydney, NSW 2000
www.boardroomlimited.com.au

Joint Lead Managers

PAC Partners Securities Pty Ltd
Level 29, 360 Collins Street
Melbourne VIC 3000
www.pacpartners.com.au

Taylor Collison Ltd
Level 10, 151 Macquarie Street
Sydney, New South Wales 2000
www.taylorcollison.com.au

Auditor

Grant Thornton Audit Pty Ltd
Collins Square, Tower 5
727 Collins Street
Melbourne, VIC 3008
www.grantthornton.com.au

Lawyers

McCullough Robertson
Level 11
66 Eagle Street
BRISBANE QLD 4000
www.mccullough.com.au

Annexure A

Attaching Option terms

Eligibility	Attaching Options to be issued to Placement Subscribers who subscribe for Placement Shares under the Placement.
Grant of Attaching Options	To be issued on the basis of one Attaching Option for every one Placement Share issued to Placement Subscribers in accordance with the terms of the Placement under the Prospectus.
Quotation of Attaching Options	The Company will not apply to ASX for official quotation of the Attaching Options.
Exercise of Options	Each Attaching Option is exercisable immediately on issue. The Attaching Options may be exercised at any time before their expiry date, wholly or in part, by delivering a duly completed form of notice of exercise together with a cheque for the exercise price. The Company will issue one Share for each Attaching Option exercised. Holders of Attaching Options may only exercise a minimum of \$1,000 of Attaching Options on any particular occasion, unless the Holder has, in total, less than \$1,000 of Attaching Options, in which case they must exercise all their Attaching Options at the same time. The exercise of each Attaching Option is subject to compliance with the Corporations Act (in particular, the requirements of Chapter 6 of the Corporations Act).
Terms of Shares issued	Any Shares issued as a result of exercising an Attaching Option will be issued on the same terms and rank in all respects on equal terms, with Existing Shares.
Transfer and security interests	Placement Subscribers may only: (a) create a security interest in; or (b) transfer, assign, dispose or otherwise deal with, Attaching Options, or any interest in Attaching Options, with the prior written consent of the Board.
Quotation of Shares issued	Application for official quotation of Shares allotted and issued as a result of the exercise of the Attaching Options will be within five business days from the date of issue of the Shares.
Expiration of Attaching Options	Each Attaching Option will expire at 5:00pm (Sydney time) on 31 December 2030.
Issue price of Attaching Options	No issue price is payable for the Attaching Options as they are issued together with any application by a Placement Subscriber for Placement Shares.
Exercise price of Attaching Options	\$0.005 upon exercise to acquire each Share.
Option register	Attaching Options will be registered in the name of a Shareholder in an option register maintained by the Company's share registry. The share registry will issue holding statements that evidence the number of Attaching Options held by the Placement Subscribers. No option certificates will be issued.

Reconstruction of capital	If there is a reconstruction (including consolidation, sub-division, reduction or return) of the issued capital of the Company: (a) the number of Attaching Options or the exercise price of the Attaching Options or both will be adjusted as specified in Listing Rule 7.22 as it applies at the time of the reorganisation; and (b) in all other respects the terms for the exercise of the Attaching Options will remain unchanged.
Adjustment where pro rata issue of Shares, bonus shares or stock dividends	There will be no adjustment to the terms of the Attaching Options if there is a pro rata issue of Shares.
New issues of Shares	The Attaching Options do not confer a right to participate in new issues of Shares unless the Attaching Options have been exercised on or before the record date for determining entitlements to the issue.
Notice of adjustments	The Company will give written notice to the Attaching Option holder of any adjustment of the exercise price of the Attaching Options and any increase or decrease in the number of Attaching Options.
Dividend rights	While they remain unexercised, the Attaching Options will not give a holder an entitlement to receive any dividends declared and paid by the Company for Shares.
Applicable law	Each Attaching Option is issued subject to: (a) the Corporations Act; (b) the Listing Rules; and (c) the Company's constitution.
US securities law restriction	The Attaching Options may not be exercised by or on behalf of a person in the United States unless the Attaching Options and the underlying shares have been registered under the <i>US Securities Act of 1933</i> and applicable US state securities laws, or exemptions from such registration requirements are available.

Annexure B

Adviser Option terms

Eligibility	Adviser Options to be issued to the Joint Lead Managers.
Grant of Adviser Options	50 million Adviser Options to be issued to PAC Partners Securities Pty Ltd and Taylor Collison Limited as Joint Lead Managers of the Equity Raise.
No Quotation of Adviser Options	The Company will not apply to ASX for official quotation of the Adviser Options.
Exercise of Options	Each Adviser Option is exercisable immediately on issue. The Adviser Options may be exercised at any time before their expiry date, wholly or in part, by delivering a duly completed form of notice of exercise together with payment for the exercise price. The Company will issue one Share for each Adviser Option exercised. Holders of Adviser Options may only exercise a minimum of \$1,000 of Adviser Options on any particular occasion, unless the Holder has, in total, less than \$1,000 of Adviser Options, in which case they must exercise all their Adviser Options at the same time. The exercise of each Adviser Options is subject to compliance with the Corporations Act (in particular, the requirements of Chapter 6 of the Corporations Act).
Terms of Shares issued	Any Shares issued as a result of exercising an Adviser Option will be issued on the same terms and rank in all respects on equal terms, with Existing Shares.
Transfer and security interests	Holders of Adviser Options may only: (a) create a security interest in; or (b) transfer, assign, dispose or otherwise deal with, Adviser Options, or any interest in Adviser Options, with the prior written consent of the Board.
Quotation of Shares issued	Application for official quotation of Shares allotted and issued as a result of the exercise of the Adviser Options will be within five business days from the date of issue of the Shares.
Expiration of Adviser Options	Each Adviser Options will expire at 5:00pm (Sydney time) on 31 March 2029.
Issue price of Adviser Options	No issue price is payable for the Adviser Options as they are issued together with any application by an Eligible Shareholder for New Shares.
Exercise price of Adviser Options	\$0.006 upon exercise to acquire each Share.
Option register	Adviser Options will be registered in the name of the holder in an option register maintained by the Company's share registry. The Share Registry will issue holding statements that evidence the number of Adviser Options held by each of the Joint Lead Managers. No option certificates will be issued.

Reconstruction of capital	If there is a reconstruction (including consolidation, sub-division, reduction or return) of the issued capital of the Company: (a) the number of Adviser Options or the exercise price of the Adviser Options or both will be adjusted as specified in Listing Rule 7.22 as it applies at the time of the reorganisation; and (b) in all other respects the terms for the exercise of the Adviser Options will remain unchanged.
Adjustment where pro rata issue of Shares, bonus shares or stock dividends	There will be no adjustment to the terms of the Adviser Options if there is a pro rata issue of Shares.
New issues of Shares	The Adviser Options do not confer a right to participate in new issues of Shares unless the Adviser Options have been exercised on or before the record date for determining entitlements to the issue.
Notice of adjustments	The Company will give written notice to the Adviser Options holder of any adjustment of the exercise price of the Adviser Options and any increase or decrease in the number of Adviser Options.
Dividend rights	While they remain unexercised, the Adviser Options will not give a holder an entitlement to receive any dividends declared and paid by the Company for Shares.
Applicable law	Each Adviser Option is issued subject to: (c) the Corporations Act; (d) the Listing Rules; and (e) the Company's constitution.
US securities law restriction	The Adviser Options may not be exercised by or on behalf of a person in the United States unless the Adviser Options and the underlying Shares have been registered under the <i>US Securities Act of 1933</i> and applicable US state securities laws, or exemptions from such registration requirements are available.

Annexure C

Convertible Note terms

Principal amount	\$4,000,000 (all amounts in A\$)
Face Value	\$1,000 per Convertible Note
Issue Date	Following shareholder approval, anticipated to be during April 2026
First Tranche	\$750,000 due the business day after EGM Shareholder Approval
Second Tranche	\$1,250,000 due by mutual agreement: (a) at least 30 business days after First Tranche (b) before the 3 year anniversary of the First Tranche, and conditional upon the share consolidation being approved by the Company's Shareholders and effected by the Company.
Third Tranche	\$1,000,000 due by mutual agreement: (a) at least 30 business days after Second Tranche (b) before the 3 year anniversary of the First Tranche and conditional upon the following: (c) Noteholder has converted out of all previous drawdowns (d) avg. daily trading volume for past 15 days is > \$25,000 (e) market capitalisation is at least \$6,000,000 (f) the Company has obtained shareholder approval or has sufficient Listing Rule 7.1 capacity to issue outstanding Warrants and other securities (g) no material change in business operations or management (h) no event of default
Fourth Tranche	\$1,000,000 due by mutual agreement: (a) at least 30 business days after Third Tranche (b) before the 3 year anniversary of the First Tranche and conditional upon the following: (c) Noteholder has converted out of all previous drawdowns (d) avg. daily trading volume for past 15 days is > \$25,000 (e) market capitalisation is at least \$6,000,000 (f) the Company has obtained shareholder approval or has sufficient Listing Rule 7.1 capacity to issue outstanding Warrants and other securities (g) no material change in business operations or management (h) no event of default
Conversion Price	A 25% discount to the lowest traded price of Shares on ASX during the 10 Actual Trading Days prior to the Conversion Notice Date
Conversion Rights	The Noteholder will have the right but not the obligation to convert the Convertible Notes into Shares.

Inability to issue Conversion Shares	If the Company is unable to issue Shares in response to a Conversion Notice, the Noteholder may (but is not required to) either: (a) hold the Conversion Price until the Company is able to issue the shares; or (b) require the Company to repay on the Maturity Date the greater of the Parity Value and that part of the Amount Outstanding that would have otherwise been the subject of such issuance (instead of issuing the Shares).
Parity Value	Parity Value, in respect of an unpaid payment or a failed Conversion, means the amount determined in accordance with the formula: PV = P ÷ CP x MV Where: PV = the Parity Value; P = the amount of the payment required to be made under this Agreement (which has not been paid); CP = the Conversion Price (in the case of a failed Conversion) that applied to the Conversion, or (in the case of an unpaid payment) determined as if the date upon which payment was required to be made was the Conversion Notice Date; and MV = the highest average VWAP of any period of 3 consecutive Trading Days during the period commencing on the date which is 5 Trading Days prior to date on which payment was required to be made and ending on the day immediately prior to the date upon which payment of the Parity Value is made.
Maturity Date	12 months from closing for each tranche
Interest rate	No interest is payable on the Convertible Notes (unless in default)
Default Interest	10% of principal amount, payable on the outstanding balance until discharged
Security	Unsecured
Default	The Agreement contains investor protections typical of such agreements, such as negative covenants and representations and warranties. Events of default include: (a) a Convertible Note or Warrant is or becomes incapable of being converted into Shares, or any securities are or become incapable of being issued under legislation; (b) the Company breaches material obligation under the agreement; (c) the Company becomes insolvent; (d) an administrator is appointed; (e) the Company ceases operations; (f) the shares are not issued within 3 business days; or (g) the Company is suspended from ASX for more than 5 trading days.
Warrant	Warranted described under a separate Warrant Deed (refer Appendix B)

Annexure D

Warrant terms

Warrants	In consideration entering into the Convertible Note Agreement, the Company grants to the Noteholder an irrevocable option for the Noteholder (or its Nominee) to require the Company to issue Warrant Shares as for the Purchase Price
Face Value	\$1,000 per Warrant
First Tranche Warrant	50% of the First Tranche Purchase Price (i.e. 50% of \$750,000 = \$375,000) 375 Warrants
Second Tranche Warrant	50% of the Second Tranche Purchase Price (i.e. 50% of \$1,250,000 = \$625,000) 625 Warrants
Third Tranche Warrant	50% of the Third Tranche Purchase Price (i.e. 50% of \$1,000,000 = \$500,000) 500 Warrants
Fourth Tranche Warrant	50% of the Fourth Tranche Purchase Price (i.e. 50% of \$1,000,000 = \$500,000) 500 Warrants
Exercise of Warrants	The number of Warrant Shares to be issued upon each exercise of a Warrant will be determined as follows, rounded up to the nearest whole number: A = B ÷ C A = the number of Warrant Shares to be issued; B = the total Face Value of the Warrant in the event of a full exercise, or in the event of a partial exercise, such amount determined by the Noteholder (Exercised Amount); C = the Exercise Price, calculated immediately prior to exercise of the Warrant.
Terms of Shares issued	Any Shares issued as a result of exercising a Warrant will be issued on the same terms and rank in all respects on equal terms, with existing Shares.
Quotation of Shares issued	The Company must apply on the Exercise Date for official quotation on the ASX of all Warrant Shares issued from the exercise of each Warrant.
Exercise Period and Expiry	Exercise Period commences the date of issue, and expires on the date 48 calendar months after that date. A Warrant that has not been exercised within the Exercise period expires at the end of the Exercise Period.
Issue price of Warrants	No issue price is payable for the Warrants as they are issued in conjunction with the Convertible Note Agreement.

Warrant Exercise Price	Exercise Price, in relation to any Warrant being exercised (whether in part or in full) means the price per Warrant Share calculated immediately prior to the time of exercise in accordance with the following formula rounded to the nearest \$0.0001, (as may be adjusted for bonus issues, pro rata issues and reorganisations of capital): $\frac{\$25,000,000}{\text{number of Shares on issue immediately before exercise of the relevant Warrant}}$
Reconstruction of capital	If there is a reconstruction (including consolidation, sub-division, reduction or return) of the issued capital of the Company, the rights of Noteholder are changed to the extent necessary to comply with the ASX Listing Rules applying to a reorganisation of capital at the time of the reorganisation.
New issues of Shares	The Warrants do not confer a right to participate in new issues of Shares unless the Warrants have been exercised on or before the record date for determining entitlements to the issue.
Dividends and voting	While they remain unexercised, the Warrants do not confer on Noteholder: (a) any entitlement to any dividends or other distributions by the Company; or (b) any right to attend or vote at any general meeting of the Company.
Applicable law	Each Warrant is issued subject to: (a) the Corporations Act; (b) the Listing Rules; and (c) the Company's constitution.
US securities law restriction	The Warrants may not be exercised by or on behalf of a person in the United States unless the Warrants and the underlying shares have been registered under the US Securities Act of 1933 and applicable US state securities laws, or exemptions from such registration requirements are available.